Although PD-L1 expression in glioblastoma has been recognized as a possible therapeutic target, more research is needed to fully understand its relationship to tumor grade and molecular features like isocitrate dehydrogenase (IDH1 R132H) mutations [8,9]. Here, IDH1 is linked to neoplasm.